EX-4.1 2 f10q0623ex4-1_immucell.htm AMENDMENT TO RIGHTS AGREEMENT BY AND BETWEEN IMMUCELL CORPORATION AND EQUINITI TRUST COMPANY, LLC DATED AUGUST 9, 2023

Exhibit 4.1

ImmuCell Corporation

AMENDMENT TO RIGHTS AGREEMENT

THIS AMENDMENT is entered into as of August 9, 2023, between IMMUCELL CORPORATION, a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC., a New York corporation, as Rights Agent (the “Rights Agent”).

WHEREAS, the Company and the Rights Agent are parties to (i) a Rights Agreement dated as of September 5, 1995, providing for the issuance of certain common stock purchase rights (the “Rights”) to holders of the Company’s outstanding Common Stock, (ii) an Amendment to the Rights Agreement, dated as of June 30, 2005, (iii) a second Amendment to Rights Agreement, dated as of June 30, 2008, (iv) a third Amendment to the Rights Agreement, dated as of August 9, 2011, (v) a fourth Amendment to the Rights Agreement, dated as of June 16, 2014, (vi) a fifth Amendment to the Rights Agreement, dated as of April 15, 2015, (vii) a sixth Amendment to the Rights Agreement, dated as of August 10, 2017 and (viii) a seventh Amendment to the Rights Agreement, dated as of August 10, 2022 (collectively, the “Rights Agreement”);

WHEREAS, under Section 7(a) of the Rights Agreement, the Rights terminate on our before the Final Expiration Date, defined in Section 1(a) of the Rights Agreement to be September 19, 2023; and

WHEREAS, the Company’s Board of Directors has determined that extending the Final Expiration Date for the Rights by one year is in the best interest of the Company;

NOW, THEREFORE, in consideration of the mutual benefits arising herefrom, the parties hereto agree as follows:

1. FINAL EXPIRATION DATE. Section 1(i) of the Rights Agreement is hereby amended to read in its entirety as follows:

“(i) “Final Expiration Date” shall mean the Close of Business on September 19, 2024.”

2. OTHER PROVISIONS. The “Summary of Rights to Purchase Common Stock” (attached to the Rights Agreement as Exhibit B thereto) shall likewise be deemed amended to reflect the change under Section 1 above. In all other respects, the terms and provisions of the Rights Agreement are hereby confirmed and shall remain in full force and effect, subject to the changes stated herein.

Signature page to follow

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and attested, all as of the date first above written.

Attest: | IMMUCELL CORPORATION |  |  |  |
By: | /s/ Elizabeth S. Toothaker |  | By: | /s/ Michael F. Brigham
| Elizabeth S. Toothaker |  |  | Michael F. Brigham
| Director of Finance and Administration |  |  | President and Chief Executive Officer
Attest: | Equiniti Trust Company, LLC |  |  |  |
By: | /s/ Joseph Dooley |  | By: | /s/ Michael Legregin
| Name: | Joseph Dooley |  |  | Name: | Michael Legregin
| Title: | Senior Vice President |  |  | Title: | Senior Vice President, Corporate Actions Relationship Management & Operations

Signature Page to Amendment to Rights Agreement